参考文献
1: Nylander S, Schulz R. Effects of P2Y12 receptor antagonists beyond platelet inhibition - comparison of ticagrelor with thienopyridines. Br J Pharmacol. 2016 Apr;173(7):1163-78. doi: 10.1111/bph.13429. Epub 2016 Feb 24. Review. PubMed PMID: 26758983.
2: Guimarães PO, Tricoci P. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? Expert Opin Pharmacother. 2015;16(13):1983-95. doi: 10.1517/14656566.2015.1074180. Epub 2015 Jul 29. Review. PubMed PMID: 26224244.
3: Bavishi C, Panwar S, Messerli FH, Bangalore S. Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome. Am J Cardiol. 2015 Sep 1;116(5):809-17. doi: 10.1016/j.amjcard.2015.05.058. Epub 2015 Jun 4. Review. PubMed PMID: 26119655.
4: Harding SA, Van Gaal WJ, Schrale R, Gunasekara A, Amerena J, Mussap CJ, Aylward PE. Practical experience with ticagrelor: an Australian and New Zealand perspective. Curr Med Res Opin. 2015 Aug;31(8):1469-77. doi: 10.1185/03007995.2015.1058247. Epub 2015 Jun 30. Review. PubMed PMID: 26086451.
5: Teng R. Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clin Pharmacokinet. 2015 Nov;54(11):1125-38. doi: 10.1007/s40262-015-0290-2. Review. PubMed PMID: 26063049; PubMed Central PMCID: PMC4621714.
6: Lemesle G, Schurtz G, Bauters C, Hamon M. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. J Thromb Haemost. 2015 Jun;13(6):931-42. doi: 10.1111/jth.12907. Epub 2015 Apr 21. Review. PubMed PMID: 25809392.
7: Dhillon S. Ticagrelor: a review of its use in adults with acute coronary syndromes. Am J Cardiovasc Drugs. 2015 Feb;15(1):51-68. doi: 10.1007/s40256-015-0108-5. Review. PubMed PMID: 25672642.
8: Chong AY, So DY. Ticagrelor for the treatment of peripheral arterial disease. Expert Opin Investig Drugs. 2014 Dec;23(12):1737-43. doi: 10.1517/13543784.2014.974803. Epub 2014 Nov 6. Review. PubMed PMID: 25376000.
9: Parodi G, Storey RF. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care. 2015 Dec;4(6):555-60. doi: 10.1177/2048872614554108. Epub 2014 Sep 29. Review. PubMed PMID: 25267878; PubMed Central PMCID: PMC4657388.
10: Alexopoulos D, Xanthopoulou I, Storey RF, Bliden KP, Tantry US, Angiolillo DJ, Gurbel PA. Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. Am Heart J. 2014 Oct;168(4):530-6. doi: 10.1016/j.ahj.2014.06.026. Epub 2014 Jul 11. Review. PubMed PMID: 25262263.
11: Rognoni A, Cavallino C, Lupi A, Secco GG, Veia A, Bacchini S, Rosso R, Brunelleschi S, Rametta F, Bongo AS. Ticagrelor: a novel drug for an old problem. Recent Pat Cardiovasc Drug Discov. 2014;9(1):51-7. Review. PubMed PMID: 25174338.
12: Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014 Oct;34(10):1077-90. doi: 10.1002/phar.1477. Epub 2014 Aug 28. Review. PubMed PMID: 25164528; PubMed Central PMCID: PMC4282310.
13: Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014 Jun 17;63(23):2503-9. doi: 10.1016/j.jacc.2014.03.031. Epub 2014 Apr 23. Review. PubMed PMID: 24768873.
14: Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Jensen EC, Sabatine MS. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J. 2014 Apr;167(4):437-444.e5. doi: 10.1016/j.ahj.2013.12.020. Epub 2014 Jan 6. Review. PubMed PMID: 24655690.
15: Bonhomme F, Fontana P, Reny JL. How to manage prasugrel and ticagrelor in daily practice. Eur J Intern Med. 2014 Mar;25(3):213-20. doi: 10.1016/j.ejim.2014.01.016. Epub 2014 Feb 12. Review. PubMed PMID: 24529662.
16: Morici N, Colombo P, Mafrici A, Oreglia JA, Klugmann S, Savonitto S. Prasugrel and ticagrelor: is there a winner? J Cardiovasc Med (Hagerstown). 2014 Jan;15(1):8-18. doi: 10.2459/JCM.0b013e328364561b. Review. PubMed PMID: 24500235.
17: Tsang K, Hartmark-Hill JR. Ticagrelor (Brilinta) for secondary prevention of thrombotic events following acute coronary syndrome. Am Fam Physician. 2013 Dec 15;88(12):821-2. Review. PubMed PMID: 24364545.
18: Serebruany VL, Sibbing D, DiNicolantonio JJ. Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond. Cardiology. 2014;127(1):20-4. doi: 10.1159/000354876. Epub 2013 Oct 26. Review. PubMed PMID: 24192670.
19: Bansilal S, Bonaca MP, Sabatine MS. Ticagrelor for acute coronary syndromes. Expert Rev Cardiovasc Ther. 2013 Nov;11(11):1473-84. doi: 10.1586/14779072.2013.839205. Epub 2013 Oct 23. Review. PubMed PMID: 24147518.
20: Norgard NB, Dinicolantonio JJ. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgrad Med. 2013 Jul;125(4):91-102. doi: 10.3810/pgm.2013.07.2682. Review. PubMed PMID: 23933898.
